Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $0.9777
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 9, 25 |
Daily · Wilder smoothing
| WBB Securities |
| upgrade |
| Hold |
| Buy |
| Jan 29, 23 | Morgan Stanley | downgrade | Equal Weight | Underweight |
| Jan 29, 23 | HC Wainwright & Co. | maintain | Buy | Buy |
| Dec 21, 22 | Oppenheimer | downgrade | Outperform | Perform |
| Sep 11, 22 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Aug 25, 22 | Alliance Global Partners | maintain | Buy | Buy |
| Aug 22, 22 | Truist Securities | maintain | Hold | Hold |
| Jun 22, 22 | HC Wainwright & Co. | maintain | Buy | Buy |
| Apr 5, 22 | Truist Securities | downgrade | Buy | Hold |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 36.55 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 4.28 | Oscillator | Buy |
| Williams %R (14) | -92.22 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.07 (Hist -0.06) | Oscillator | Strong Sell |
| Average Directional Index (14) | 23.53 (+DI 16.5 / -DI 28.7) | Trend | Sell |
| EMA 20 | 1.27 | MA | Strong Sell |
| SMA 20 | 1.36 | MA | Strong Sell |
| EMA 50 | 1.25 | MA | Strong Sell |
| SMA 50 | 1.31 | MA | Strong Sell |
| SMA 200 | 1.10 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 23, 26 | Philip & Daniele Barach Family Trust | 10 percent owner | J-Other | 2,140,000 @ $1.50 | $3.21M |
| Sep 23, 26 | Philip & Daniele Barach Family Trust | 10 percent owner | J-Other | 192,771 @ $1.50 | $289.2K |
| Sep 23, 26 | Philip & Daniele Barach Family Trust | 10 percent owner | J-Other | 1,457,765 @ $2.00 | $2.92M |
| Sep 23, 26 | Philip & Daniele Barach Family Trust | 10 percent owner | J-Other | 1,457,765 @ $2.00 | $2.92M |
| Sep 23, 26 | Philip & Daniele Barach Family Trust | 10 percent owner | J-Other | 1,177,000 @ $1.50 | $1.77M |
| Sep 23, 26 | Barach Daniele Wolf | 10 percent owner | J-Other | 2,140,000 @ $1.50 | $3.21M |
| Sep 23, 26 | Barach Daniele Wolf | 10 percent owner | J-Other | 192,771 @ $1.50 | $289.2K |
| Sep 23, 26 | Barach Daniele Wolf | 10 percent owner | J-Other | 1,457,765 @ $2.00 | $2.92M |
FY2025 · 10-K disclosure
TTM vs. 5-year historical average (annual ratios)
| Metric | CELU | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.5x | 1.0x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.4x | EPS est. -2.75 | Discount |
| Price / Book | -0.8x | 2.6x | Discount |
| Price / Sales | 1.7x | 8.9x | Discount |
| EV / EBITDA | -1.9x | -2.6x | Discount |
| Return on equity | 142.3% | — | Top tier |
| Gross margin | 19.2% | 34.4% | Below hist. |
| Debt / Equity | -1.01 | 1.79 | Conservative |
| Piotroski / Altman Z | 3/9 | Z -16.21 | Distress |
Discounted cash flow model
Stock news · updated daily
FLORHAM PARK, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced that it received written confirmation from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) that Celularity has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the U.S. Securities and Exchange Commission.
Celularity highlights Fontaine Vitale's planned Q1 2027 opening in Bali, creating potential new revenue opportunities in Asia-Pacific regenerative medicine
FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative medicine company, today announced that Naveen Jain, founder and Chief Executive Officer of Viome Life Sciences Inc. (“Viome”), will join its Board of Directors.
Celularity closes $10 million financing in an up to $28 million recapitalization, advancing growth and targeting positive operating cash flow by Q1 2027.
[url="]Celularity Inc.[/url] (Nasdaq: CELU) (âCelularityâ), a longevity-focused regenerative and cellular medicine company, and [url="]MuseCell InnovationsÂ
FLORHAM PARK, N.J. & SINGAPORE--(BUSINESS WIRE)--Celularity Inc. and MuseCell Innovations announce U.S. manufacturing partnership for production of Dezawa MuseCells in Florham Park, NJ facility.
FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that, because the Company has not filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026 and remains delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Oct 20, 2026 | — | -0.12 | — | — |
| Sep 29, 2026 | — | 0.02 | — | $5.43M |
| Apr 30, 2026 | -1.50 | -0.95 | Beat 36.7% | $4.10M |
| Nov 14, 2025 | -1.50 | -0.88 | Beat 41.3% | $5.28M |
| Aug 29, 2025 | — | -0.75 | — | $5.74M |
| May 8, 2025 | -1.50 | -0.84 | Beat 44.0% | $11.43M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 10-Q | Oct 20, 2026 | 2026-10-20 17:08:32 | View |
| 10-K/A | Oct 20, 2026 | 2026-10-20 09:15:16 | View |
| 8-K | Sep 29, 2026 | 2026-09-29 17:25:51 | View |
| 10-Q | Sep 29, 2026 | 2026-09-29 17:02:05 | View |
| SC 13D/A | Sep 28, 2026 | 2026-09-28 13:14:00 | View |
| 8-K | Sep 28, 2026 | 2026-09-28 06:14:09 | View |
| 4 | Sep 25, 2026 | 2026-09-25 16:59:56 | View |
| 4 | Sep 25, 2026 | 2026-09-25 16:58:29 | View |
| 4 | Sep 25, 2026 | 2026-09-25 16:57:42 | View |
| 8-K | Sep 14, 2026 | 2026-09-14 09:00:45 | View |
Proxy statement (DEF 14A) disclosures
